Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 4901591, 8 pages
https://doi.org/10.1155/2018/4901591
Research Article

T-614 Promotes Osteoblastic Cell Differentiation by Increasing Dlx5 Expression and Regulating the Activation of p38 and NF-κB

1Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Immunology, 280 South Chongqing Road, Shanghai 200025, China
2Guanghua Rheumatology Hospital, 540 Xinhua Road, Shanghai 200052, China
3The Fifth People’s Hospital of Yuhang District, Hangzhou 311100, China

Correspondence should be addressed to Dongyi He; nc.moc.liamdem@ehiygnod and Guangjie Chen; moc.361@nehc_eijgnaug

Received 5 August 2017; Revised 7 December 2017; Accepted 1 January 2018; Published 19 February 2018

Academic Editor: Zbigniew Gugala

Copyright © 2018 Jinglue Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Chen, “Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells,” Archivum Immunologiae et Therapia Experimentalis, vol. 58, no. 1, pp. 27–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Komatsu and H. Takayanagi, “Autoimmune Arthritis. The Interface Between the Immune System and Joints.,” Advances in Immunology, vol. 115, pp. 45–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Xu, Q. Zhu, J. Song et al., “Regulatory effect of iguratimod on the balance of th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis,” Mediators of Inflammation, vol. 2015, Article ID 356040, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Du, L.-J. Lü, Q. Fu et al., “T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis,” Arthritis Research & Therapy, vol. 10, no. 6, article R136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Wei, X. Sun, M. Hua, W. Tan, F. Wang, and M. Zhang, “Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients,” BioMed Research International, vol. 2015, Article ID 214683, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Murao, N. Omatsu, Y. Aikawa, and K. Tanaka, “a disease-modifying antirheumatic drug, suppressed osteoclast differentiation in vitro,” International Journal of Rheumatic Diseases, p. 11, 2008. View at Google Scholar
  7. K. Kuriyama, C. Higuchi, K. Tanaka, H. Yoshikawa, and K. Itoh, “A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo,” Biochemical and Biophysical Research Communications, vol. 299, no. 5, pp. 903–909, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Beyer Nardi and L. da Silva Meirelles, “Mesenchymal Stem Cells: Isolation, In Vitro Expansion and Characterization,” in Stem Cells, vol. 174 of Handbook of Experimental Pharmacology, pp. 249–282, Springer Berlin Heidelberg, Berlin, Heidelberg, 2006. View at Publisher · View at Google Scholar
  9. O. O. Oni, “Early histological and ultrastructural changes in medullary fracture callus.,” The Journal of Bone & Joint Surgery, vol. 74, no. 4, pp. 633-634, 1992. View at Publisher · View at Google Scholar
  10. C. T. Brighton and R. M. Hunt, “Early histologic and ultrastructural changes in microvessels of periosteal callus,” Journal of Orthopaedic Trauma, vol. 11, no. 4, pp. 244–253, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Okamura, Y. Yonemoto, C. Okura, T. Kobayashi, and K. Takagishi, “Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 25, no. 2, pp. 235–240, 2015. View at Publisher · View at Google Scholar
  13. K. Okamura, Y. Yonemoto, T. Suto, C. Okura, and K. Takagishi, “Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 25, no. 4, pp. 534–539, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. L.-J. Lu, C.-D. Bao, M. Dai et al., “Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate,” Arthritis Care & Research, vol. 61, no. 7, pp. 979–987, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ishiguro, K. Yamamoto, K. Katayama et al., “Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial,” Modern Rheumatology, vol. 23, no. 3, pp. 430–439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Humby, A. Mahto, M. Ahmed et al., “The relationship between synovial pathobiology and magnetic resonance imaging abnormalities in rheumatoid arthritis: A systematic review,” The Journal of Rheumatology, vol. 44, no. 9, pp. 1311–1324, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. Tu, P. Valverde, and J. Chen, “Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells,” Biochemical and Biophysical Research Communications, vol. 341, no. 4, pp. 1257–1265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Nakashima, X. Zhou, G. Kunkel et al., “The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation,” Cell, vol. 108, no. 1, pp. 17–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. Z.-L. Deng, K. A. Sharff, N. Tang et al., “Regulation of osteogenic differentiation during skeletal development,” Frontiers in Bioscience, vol. 13, no. 6, pp. 2001–2021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Vortkamp, “Interaction of growth factors regulating chondrocyte differentiation in the developing embryo,” Osteoarthritis and Cartilage, vol. 9, pp. S109–S117, 2001. View at Google Scholar · View at Scopus
  21. A. Ulsamer, M. J. Ortuño, S. Ruiz et al., “BMP-2 induces osterix expression through up-regulation of Dlx5 and its phosphorylation by p38,” The Journal of Biological Chemistry, vol. 283, no. 7, pp. 3816–3826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. M. Brennan and I. B. McInnes, “Evidence that cytokines play a role in rheumatoid arthritis,” The Journal of Clinical Investigation, vol. 118, no. 11, pp. 3537–3545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Safadi, T. Mbimba, G. Sondag, F. Moussa, and S. Abdelmagid, “TRAPPC9 Regulates BMP2-mediated Osteoblast Differentiation through Down-Regulation of NF-kB Activation,” Journal of Bone and Mineral Research, vol. 17, pp. 415–424, 2014. View at Google Scholar
  24. M. Yamaguchi, J. L. Arbiser, and M. N. Weitzmann, “Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation,” International Journal of Molecular Medicine, vol. 28, no. 6, pp. 1049–1053, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Sakurai, H. Chiba, H. Miyoshi, T. Sugita, and W. Toriumi, “IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain,” The Journal of Biological Chemistry, vol. 274, no. 43, pp. 30353–30356, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Milanovic, M. Kracht, and M. Lienhard Schmitz, “The cytokine-induced conformational switch of nuclear factor κb p65 is mediated by p65 phosphorylation,” Biochemical Journal, vol. 457, no. 3, pp. 401–413, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Geng, T. Wittwer, O. Dittrich-Breiholz, M. Kracht, and M. L. Schmitz, “Phosphorylation of NF-κB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination,” EMBO Reports, vol. 10, no. 4, pp. 381–386, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Aikawa, M. Yamamoto, T. Yamamoto, K. Morimoto, and K. Tanaka, “An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation,” Inflammation Research, vol. 51, no. 4, pp. 188–194, 2002. View at Publisher · View at Google Scholar · View at Scopus